Tomasz Sewastianik is a translational scientist with a focus on the molecular biology of normal and malignant lymphoid cells and the clinical exploitation of validated signaling, transcriptional, and metabolic pathways. He obtained his MSc in 2011 from Maria Curie-Sklodowska University in Lublin, Poland, under the auspices of the Nencki Institute of Experimental Biology, Polish Academy of Sciences in Warsaw, where he worked in the area of DNA damage response and T cells death associated with immune system deterioration. He then obtained a PhD in 2015 under Prof. Przemyslaw Juszczynski at the Maria Sklodowska-Curie Memorial Cancer Center – Institute of Oncology and at the Institute of Hematology and Transfusion Medicine in Warsaw, where he studied redox-dependent signaling pathways in diffuse large B-cell lymphoma (DLBCL) and identified the TXN-p300-FOXO1 circuit as the major mediator of oxidative stress response in DLBCL. He also worked on the inhibition of PIM kinases in acute myeloid leukemia and on daunorubicin-resistance in acute lymphoblastic leukemia cells. In 2015, he began postdoctoral training with Dr. Ruben Carrasco at Dana-Farber Cancer Institute, working on mouse models of cancer using, for example, animals with mutated MYD88 protein overexpression, miR-15a/16-1 deletion, and Kras oncogene mutation with concomitant deletion of the Ink4a/Arf tumor suppressor. He has published in peer-reviewed journals and has presented his findings at international meetings including, for example, American Society of Hematology Annual Meetings and the International Conference on Malignant Lymphoma in Lugano, Switzerland.
